What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

Bronsard, V.; Paul, C.; Prey, S.; Puzenat, E.; Gourraud, Pierre-Antoine; Aractingi, S.; Aubin, F.; Bagot, Martine; Cribier, B.; Joly, P.; Jullien, D.; Maître, Michel; Richard-Lallemand, M.-A.; Ortonne, Jean‐Paul

doi:10.1111/j.1468-3083.2009.03563.x

Cited by 125 publications

(118 citation statements)

References 16 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…The DLQI is a reliable and valid instrument [7,10,11] . However, it has fallen short in some other aspects of psychometric performance in particular unidimensionality and item bias [12][13][14][15] . Hongbo et al [16] have demonstrated a banding system to aid the interpretation of DLQI scores, but a frequent question still arises: what does a specific improvement, such as 2, 5 or 6 points, in a DLQI score mean to a patient (and to the physician)?…”

Section: Introductionmentioning

confidence: 99%

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

et al. 2015

View full text Add to dashboard Cite

Aims: To determine the minimal clinically important difference (MCID) of the Dermatology Life Quality Index (DLQI) and its responsiveness to change in inflammatory skin diseases. Methods: A longitudinal study: at stage 1, patients completed the DLQI and a disease severity global question; at stage 2, a global rating of change in quality of life (QoL; Global Rating of Change Questionnaire, GRCQ) was added and used as an anchor to measure the MCID of the DLQI. Results: 192 patients completed stage 1 and 107 completed stage 2. The mean DLQI score at stage 1 was 9.8 and 7.4 at stage 2 with a mean change of 2.4 (p < 0.0001). 31 patients experienced a ‘small change' in their QoL (±3 and ±2) on the GRCQ. The mean corresponding change in DLQI scores was 3.3, which is regarded as the approximate MCID. Conclusions: Previous estimates of the MCID of the DLQI have varied from 3 to 5. Although this study demonstrated a MCID of 3.3, we recommend that the MCID in inflammatory skin diseases should be 4.

show abstract

Section: Introductionmentioning

confidence: 99%

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Whereas the clinical measure psoriasis area and severity index (PASI) and the dermatology-specific HRQOL measure dermatology quality of life index (DLQI) are widely used and valid measures in psoriasis [11,12,13,14,15,16,17]; the generic preference-based EQ-5D questionnaire is a good complement [18], essential in cost-effectiveness analyses [19]. …”

Section: Introductionmentioning

confidence: 99%

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

et al. 2012

View full text Add to dashboard Cite

Background: Although clinical studies have shown efficacy of biological agents in moderate to severe psoriasis, observational studies of real-world effectiveness are rare. Objective: To analyse the psoriasis area and severity index (PASI) and quality of life by the EQ-5D questionnaire and dermatology quality of life index (DLQI) in psoriasis patients who switched from conventional systemic treatment to biological agents in clinical practice. Furthermore, to analyse patient groups with the highest benefit of biological agents. Methods: Longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Pso-riasis, PsoReg. Outcomes of biological-naïve patients who switched to a biological agent (n = 267) were analysed before switch and at the first follow-up. Results: Patients significantly improved in EQ-5D, DLQI and PASI (p < 0.001). Patients with DLQI ≥10 and/or PASI ≥10 had the greatest benefits from biological agents in terms of EQ-5D. Conclusions: Patients with moderate to severe psoriasis benefit from biological agents in clinical practice; the patients with the highest benefits were those with high pretreatment PASI and DLQI scores.

show abstract

“…A survey of National Psoriasis Foundation members also found a high rate of dissatisfaction with treatment among psoriasis patients (52.3%) and PsA patients (45.5%), and cited adverse effects and efficacy as the main reasons for discontinuation of biologic therapy. Patient-reported outcomes, such as health-related quality of life measures, have been increasingly studied in large randomized trials of psoriasis therapies since conventional clinical measures do not fully inform the effects of disease and treatment on patients [32,33]. Commonly used health-related quality of life measures focus on the impact of the disease on physical, psychological, and social functioning, but not the impact of the treatment experience on these factors.…”

Section: Discussionmentioning

confidence: 99%

Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study

Radtke¹,

Spehr²,

Reich³

et al. 2016

Dermatology

View full text Add to dashboard Cite

Introduction: Evidence supports the potential value of matching patient preferences to treatment recommendations. The aim of the study was to design and validate a questionnaire on treatment satisfaction for clinical decision-making. Methods: We performed a comprehensive literature search identifying measurable indicators. The complete item pool was condensed to a core set by a multidisciplinary expert panel and tested in a multicentre, observational, cross-sectional study. Results: The questionnaire consisted of 8 questions, rated on a 5-point Likert scale. In total, 213 dermatology centres included 2,084 patients. The mean disease duration was 19 years. A majority of patients (82.8%) was moderately to very satisfied. 108 patients (5.8%) felt to be bothered by side effects, and 32.1% ascertained that the current therapy had been conducted for too long without success. Discussion: The PsoSat Questionnaire was shown to be a reliable and valid instrument for measuring therapy-related satisfaction. Further research on its implementation in clinical decision-making is necessary to finally evaluate the benefit of this tool.

show abstract

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

Cited by 125 publications

References 16 publications

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study

Contact Info

Product

Resources

About